HUP0500478A2 - Taxánszármazékokat tartalmazó tumorellenes készítmények - Google Patents

Taxánszármazékokat tartalmazó tumorellenes készítmények

Info

Publication number
HUP0500478A2
HUP0500478A2 HU0500478A HUP0500478A HUP0500478A2 HU P0500478 A2 HUP0500478 A2 HU P0500478A2 HU 0500478 A HU0500478 A HU 0500478A HU P0500478 A HUP0500478 A HU P0500478A HU P0500478 A2 HUP0500478 A2 HU P0500478A2
Authority
HU
Hungary
Prior art keywords
compositions containing
taxane derivatives
containing taxane
antitumor compositions
antitumor
Prior art date
Application number
HU0500478A
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HUP0500478A2 publication Critical patent/HUP0500478A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A találmány szerinti gyógyászati kombináció (I) általános képletűvegyületet vagy annak származékát és legalább egy alkilezőszert,antimetabolitot, sejtorsómérget, epidofillotoxint, antibiotikumot,enzimet, topoizomeráz inhibitort, platina koordinációs komplexet,biológiaiválasz-módosítót vagy növekedési faktor inhibitort tartalmaz.A találmány szerinti kombinációk neopláziás betegségek kezelésérehasználhatók.
HU0500478A 2001-03-21 2002-03-21 Taxánszármazékokat tartalmazó tumorellenes készítmények HUP0500478A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/813,018 US6441026B1 (en) 1993-11-08 2001-03-21 Antitumor compositions containing taxane derivatives
PCT/IB2002/000853 WO2002074289A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives

Publications (1)

Publication Number Publication Date
HUP0500478A2 true HUP0500478A2 (hu) 2005-08-29

Family

ID=25211230

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500478A HUP0500478A2 (hu) 2001-03-21 2002-03-21 Taxánszármazékokat tartalmazó tumorellenes készítmények

Country Status (19)

Country Link
US (1) US6441026B1 (hu)
EP (1) EP1478355B1 (hu)
JP (1) JP4467885B2 (hu)
CN (2) CN101590057A (hu)
AT (1) ATE355837T1 (hu)
AU (1) AU2002244877B2 (hu)
BR (1) BR0208274A (hu)
CA (1) CA2440160C (hu)
CY (1) CY1106582T1 (hu)
DE (1) DE60218751T2 (hu)
DK (1) DK1478355T3 (hu)
EA (1) EA006878B1 (hu)
ES (1) ES2282400T3 (hu)
HU (1) HUP0500478A2 (hu)
IL (1) IL157992A (hu)
MX (1) MXPA03008539A (hu)
PT (1) PT1478355E (hu)
SI (1) SI1478355T1 (hu)
WO (2) WO2002074289A2 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
KR20040025904A (ko) * 2001-03-14 2004-03-26 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 에포틸론 유사체 및화학치료제의 병용
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ME00055B (me) * 2002-05-17 2010-10-10 Aventis Pharma Sa Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
EP1663153A4 (en) * 2003-05-20 2011-01-05 Aronex Pharmaceuticals Inc COMBINATION SCHEMOTHERAPY WITH A LIPOSOMAL PLATINUM COMPLEX
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
KR101764375B1 (ko) 2005-02-18 2017-08-03 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2631704A1 (en) 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
WO2008124735A2 (en) * 2007-04-10 2008-10-16 Nitto Denko Corporation Multi-functional polyglutamate drug carriers
US20080279782A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polymers conjugated with platinum drugs
DK2155255T3 (da) 2007-05-09 2013-09-02 Nitto Denko Corp Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat
EP2155253A2 (en) * 2007-05-09 2010-02-24 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
JP2011513412A (ja) * 2008-03-06 2011-04-28 日東電工株式会社 ポリマーパクリタキセル結合体を含む癌を治療するための薬学組成物
JP5926724B2 (ja) 2010-03-29 2016-05-25 アブラクシス バイオサイエンス， エルエルシー がんを処置する方法
CN107158389A (zh) 2010-03-29 2017-09-15 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
BR112013011590A2 (pt) * 2010-11-12 2019-09-24 Endocyte Inc método de tratamento de câncer
CN102241648B (zh) * 2011-01-31 2016-08-03 沈阳东星医药科技有限公司 抗多药耐药紫杉烷类衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU2005692A (en) 1991-05-08 1992-12-21 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5284865A (en) 1991-09-23 1994-02-08 Holton Robert A Cyclohexyl substituted taxanes and pharmaceutical compositions containing them
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0982028A1 (en) * 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives

Also Published As

Publication number Publication date
US6441026B1 (en) 2002-08-27
CN101590057A (zh) 2009-12-02
WO2002074289A2 (en) 2002-09-26
EP1478355B1 (en) 2007-03-07
WO2002074289A3 (en) 2004-09-02
AU2002244877B2 (en) 2006-07-20
CA2440160C (en) 2011-07-05
US20020031505A1 (en) 2002-03-14
JP2004536790A (ja) 2004-12-09
DK1478355T3 (da) 2007-07-02
JP4467885B2 (ja) 2010-05-26
CN1536995A (zh) 2004-10-13
ATE355837T1 (de) 2007-03-15
CY1106582T1 (el) 2012-01-25
IL157992A (en) 2008-08-07
PT1478355E (pt) 2007-05-31
EP1478355A2 (en) 2004-11-24
CA2440160A1 (en) 2002-09-26
ES2282400T3 (es) 2007-10-16
WO2002074232A2 (en) 2002-09-26
DE60218751D1 (de) 2007-04-19
EA006878B1 (ru) 2006-04-28
EA200301047A1 (ru) 2004-06-24
SI1478355T1 (sl) 2007-08-31
MXPA03008539A (es) 2004-08-11
DE60218751T2 (de) 2007-11-22
BR0208274A (pt) 2004-07-13

Similar Documents

Publication Publication Date Title
HUP0500478A2 (hu) Taxánszármazékokat tartalmazó tumorellenes készítmények
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
AU2002239344A1 (en) Pyrazolopyridines
BR0208741A (pt) Derivados de piperidina
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
ES2243579T3 (es) Derivados de pirazolopirideno.
SE0101932D0 (sv) Pharmaceutical combinations
ATE233754T1 (de) Diphenyl-piperidin derivate
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP0300848A2 (hu) Kamptotecint és egy pirimidinszármazékot tartalmazó készítmény rák kezelésére
SE9902551D0 (sv) Novel compounds
AU2002248531A1 (en) Pyrazolopyriadine derivatives
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
SE9904128D0 (sv) Novel compounds
BR0014687A (pt) Compostos de taxano pentacìclico
DE60130009D1 (de) Makrolide
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
TR199801835A2 (xx) Antimikrobiyal kompozisyonlar.
MXPA03003466A (es) Derivados de piranosido.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees